Parkinson’s

Neurons
#Dementia #Neurodegenerative disorders #Parkinson's #Peptides #University of Bath

Scientists design peptide ‘switch’ to slow Parkinson’s progress

Researchers at the University of Bath, in collaboration with the Universities of Oxford and Bristol, have developed a molecule that prevents the clumping and build-up of alpha-synuclein, a protein linked to Parkinson’s disease and related dementias.   The team has successfully demonstrated it works in an animal model… Read More

#News #Trending News

Brain physiology
#Neurodegenerative disorders #Neuroscience #Parkinson's #Phase I trial

Early-stage advances in Parkinson’s drug discovery

A number of key clinical and preclinical study results into potential Parkinson’s disease (PD) therapeutics were announced at the International Congress of Parkinson’s Disease and Movement Disorders.  Unexpected early results for allosteric enzyme modulator Gain Therapeutics shared encouraging early results from the Phase Ib clinical study of GT-02287 in people… Read More

#Exclusive Content

Parkinson's disease
#Financing #Mission Therapeutics #Parkinson's

Mission Therapeutics raises $13.3 million for Parkinson’s treatment

Biotech company Mission Therapeutics has raised $13.3 million to progress the clinical development of its lead candidate for the treatment of Parkinson’s disease.  The lead candidate MTX35 works by inhibiting USP30, a mitochondrial de-ubiquitylating enzyme (DUB), increasing mitochondrial ubiquitylation and promoting appropriate mitophagy. This is the essential process cells use… Read More

#Business & Investment #News

Neuroscience Parkinson's disease
#Parkinson's

Positive results announced for Parkinson’s treatment ARV-102  

Biotechnology company Arvinas has announced positive results for its Phase I clinical trial of ARV-102 in Parkinson’s disease.  The results, presented at the International Congress of Parkinson’s Disease and Movement Disorders in Honolulu, show positive pharmacokinetic, pharmacodynamic, and biomarker data from two Phase I clinical trials evaluating… Read More

#News

Neuron
#Gain Therapeutics #Neurodegenerative disorders #Neuroscience #Parkinson's #Phase I trial

Early data suggest GT-02287 slows Parkinson’s disease

Gain Therapeutics has shared early safety and tolerability findings, the primary endpoint, and observations from key exploratory endpoints from the Phase Ib clinical study of GT-02287 in people with Parkinson’s disease (PD) with or without a GBA1 mutation.  The findings were presented in a poster at the… Read More

#News #Trending News

#Drug discovery #Funding #Neuroscience #Parkinson's #The Michael J Fox Foundation for Parkinson’s Research (MJFF)

Lys Therapeutics awarded $5m to advance neuro pipeline  

French biotech Lys Therapeutics has received a grant award of $5 million (£3.6 million) from The Michael J Fox Foundation for Parkinson’s Research (MJFF) to accelerate the clinical development of its first-in-class monoclonal antibody for the treatment of Parkinson’s disease and other neurodegenerative disorders.  The funding… Read More

#News

#Clinical trial #Drug discovery #Gene therapy #Neuroscience #Parkinson's

AskBio begins second phase of gene therapy trial for Parkinson’s  

The first European patients have been randomised in a Phase II gene therapy clinical trial for Parkinson’s disease (PD), AskBio has announced.   The REGENERATE-PD clinical trial is evaluating the safety and efficacy of AskBio’s investigational gene therapy AB-1005 and will enrol approximately 87 patients across clinical trial… Read More

#Editor's Choice #News

Neurons in Parkinson's disease
#Neuroinflammation #Neuroscience #NodThera #Parkinson's #Phase II trial

Oral NLRP3 inhibitor reverses neuroinflammation in Parkinson’s

NodThera has shared positive data from its Parkinson’s disease Phase Ib/IIa study evaluating the effects of NT-0796, its oral, brain-penetrant NLRP3 inflammasome inhibitor.  In the first publication to demonstrate the clinical potential of an oral, fully brain-penetrant NLRP3 inhibitor in Parkinson’s disease, NT-0796 was shown to be… Read More

#News

Neuroscience
#Collaboration #JAK inhibitor #Neuroinflammation #Parkinson's #Receptor.AI #Sareum Holdings

Sareum and ReceptorAI collaborate on TYK2/JAK1 inhibitors

Sareum Holdings and Receptor.AI have entered into a strategic collaboration focused on accelerating the discovery and optimisation of blood-brain barrier (BBB)-permeable, isoform-selective TYK2/JAK1 inhibitors.  The goal of the agreement is to generate high-quality candidates suitable for preclinical development in neuroinflammatory indications, such as multiple sclerosis and Parkinson’s disease.   Sareum’s previously… Read More

#Business & Investment #News

Brain physiology
#Alzheimer's #Biomarkers #Neurodegenerative disorders #Parkinson's #Proteomics

Uncovering biomarkers of ageing and neurodegenerative disease

The Global Neurodegeneration Proteomics Consortium (GNPC) has released research analyses of one of the world’s largest protein datasets in order offer new insights into the biological underpinnings of major neurodegenerative diseases, such as Alzheimer’s disease and Parkinson’s disease. The findings, published in a series of papers in Nature Medicine, reveal… Read More

#News

Degeneration of dopaminergic neuron in Parkinson's disease
#Depression #Drug repurposing #Parkinson's #Psychiatry #Treatment-resistant depression #University of Oxford

Dopamine-boosting Parkinson’s drug treats depression

A drug used for Parkinson’s disease has been shown to be effective in reducing the symptoms of difficult to treat depression, in a study led by the University of Oxford.  In the largest clinical trial to date, pramipexole was found to be substantially more effective than a… Read More

#Editor's Choice #News

Brain neurons in lysosomal storage diseases
#Casma Therapeutics #Neurodegenerative disorders #Neuroscience #Parkinson's

Casma takes a new therapeutic approach to neurodegeneration

Casma Therapeutics has nominated its first development candidate, CSM-101, a first-in-class TRPML1 agonist, marking a new therapeutic approach for targeting lysosomal dysfunction in genetically driven neurodegenerative diseases.  CSM-101 is being developed for the treatment of Gaucher’s disease patients with Parkinson’s disease (GD-PD), with the potential to expand… Read More

#News

#BIAL #Biopharmaceuticals #Neuroscience #Parkinson's #Rare diseases

BIAL to present at GBA1 Meeting 2025 on Parkinson’s treatment

BIAL, a biopharmaceutical company focused on neurosciences and rare diseases, will give an oral presentation on its potential disease-modifying compound, BIA 28-6156, at the GBA1 Meeting 2025 being held 5-7 June 2025, in Montreal, Canada. The GBA1 Meeting 2025 is hosted by McGill University, focusing on all aspects of GBA1… Read More

#News

Neurones in the brain
#Neuroscience #Parkinson's #University of Queensland

Breakthrough could boost quality of life for people with Parkinson’s disease

University of Queensland researchers have found that Gherlin, the natural ‘hunger hormone’, could be the key to preventing debilitating chronic constipation experienced by people living with Parkinson’s disease. Associate Professor Sebastian Furness from the UQ School of Biomedical Sciences said the team discovered the body’s receptor for Ghrelin had a… Read More

#News

Neuron firing
#Clinical trials #Herantis Pharma #Parkinson's #The Michael J Fox Foundation for Parkinson’s Research (MJFF)

First patients dosed in Phase Ib Parkinson’s disease trial

Herantis Pharma has dosed the first patients in the final cohort of its Phase Ib clinical trial evaluating the safety and tolerability of HER-096 in patients with Parkinson’s disease. Commenting on the study, Antti Vuolanto, CEO of Herantis Pharma, said: “Parkinson’s disease is a life altering condition, and there is… Read More

#News

Parkinson's disease
#Neurodegenerative disorders #Neuroscience #Parkinson's #University of Cambridge

Research reveals “compelling” new drug target for Parkinson’s

Researchers have identified a key enzyme driving forms of Parkinson’s, offering a promising new drug target for the condition.  In Parkinson’s, a protein known as alpha-synuclein builds up in clumps called Lewy bodies in nerve cells in the brain. These clumps of protein stop these cells from… Read More

#Editor's Choice #News